← Leaderboards
Minzhen Xu
Antigen Express, Inc.
$1,560,653
Attributed
$1,560,653
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,560,653 · 5
By mechanism
R43$1,560,653 · 5
Top collaborators
No co-investigators on record.
Most similar at Antigen Express, Inc.
Same institution · by research overlap
- Robert E Humphreys$416,444
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentMhc Class Ii AntigenLaboratory MouseInvariant ChainNeoplasm /Cancer VaccineMolecular CloningVector VaccineTumor AntigensGene TherapyAids VaccinesSynthetic VaccinesTransfection /Expression VectorDosageDendritic CellsBiotechnologyCombination Cancer TherapyHiv Envelope Protein Gp120Colon NeoplasmsAntisense Nucleic AcidHelper T LymphocyteGenetic PolymorphismClinical ResearchGenetically Modified AnimalsChimeric Proteins
Grant awards (5)
li-Key/Melanoma MHC Class II Vaccines$444,070
R43 · FY2003 · CA
li Suppression-enhanced HIV DNA Vaccine$354,100
R43 · FY2003 · AI
HIV li-Key/Peptide Vaccine$301,761
R43 · FY2002 · AI
COMBINED IL-2 AND MHC CLASS II GENE THERAPY FOR CANCER$287,382
R43 · FY2001 · CA
MHC CLASS II BASED TUMOR VACCINE$173,340
R43 · FY2000 · CA